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ABSTRACT:  
Many of the breast cancer treatments use chemotherapeutic agents in the form of synthetic drugs. Some thiourea 
and benzoylurea derivatives have been proven to inhibit the proliferation of breast cancer cells. Up until now, the 
derivation compounds are still being developed. In this study, we synthesized two compounds namely N-(4-
bromo)-benzoyl-N'-phenylthiourea and 4-(tert-butyl)-N-benzoylurea. Before the two compounds were 
synthesized, the prediction of cytotoxic activity in silico was first performed by docking the synthesis 
compounds with the HER2 receptor (PDB code: 3PP0). The results of the in-silico test are Rerank Score (RS) 
value using the MVD program (Molegro Virtual Doker). Acyl nucleophilic substitution was carried out to 
synthesize the compounds. The structure of the synthesized compounds was identified using FTIR, 1H-NMR, 
13C-NMR and Mass Spectrometry. In vitro cytotoxic activity was carried out on HER2-positive primary breast 
cancer cells and produced IC50 values. The results showed that the RS value of N-(4-bromo)-benzoyl-N'-
phenylthiourea was smaller (-99.21kcal/mol) than 4-(tert-butyl)-N-benzoylurea (-88.86kcal/mol), meanwhile the 
RS value of hydroxyurea as a comparison compound which has a urea group and anticancer activity of -
34.60kcal/mol. IC50 values of N-(4-bromo)-benzoyl-N’-phenylthiourea and 4-(tert-butyl)-N-benzoylurea were 
0.54 mM and 0.61mM respectively. Hydroxyurea had an IC50 value of 11.61mM. It can be concluded that N-(4-
bromo)-benzoyl-N’-phenylthiourea was more potent than 4-(tert-butyl)-N-benzoylurea so it can be developed 
further as an anticancer candidate for HER2-positive breast cancer. 
 




Cancer is one of the major health burdens of disease in 
the world. Breast cancer ranks second in mortality after 
lung cancer and spreads fear to women around the 
world1. Cancer treatment options vary greatly depending 
on the stage of cancer at the time of diagnosis. 
Radiotherapy and surgery are commonly used in the 
early stages of breast cancer. Chemotherapy is cancer 
treatment options at an advanced stage of the disease2,3. 
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The use of chemotherapy is often limited predominantly 
due to unwanted side effects and limited choices of 
anticancer drugs4. Thus, the success of cancer treatment 
is a challenge in the 21st century. It underlines the need 
for developing new chemotherapy drugs with higher 
anticancer activity. 
 
Many cancer drugs are developed through growth factor 
receptors (GFR) as targets of action. GFR kinases, 
known to play an important role in cancer are the 
epidermal growth factor receptor (EGFR or erbB-1) and 
human epidermal growth factor receptor-2 (erbB-2 or 
HER2). In the cases of breast cancer, 30% incidences are 
caused by overexpression of Human Epidermal Receptor 
2 (HER2) with a poor prognosis5. 




The treatment that is currently widely used in handling 
breast cancer is using chemotherapy agents in the form 
of synthetic drugs. Thiourea derivative is an anticancer 
agent acting as an EGFR inhibitor. It inhibited Receptor 
Tyrosine Kinases (RTKs) in the intracellular region6. Li 
synthesized and looked at the structural relationship of 
the activities of the N-benzyl-N-(X-2-hydroxybenzyl)-
N'-phenylureas and thioureas derivatives as anticancer. 
The results obtained that the compound derivatives 
proved to be as potential EGFR and HER2 kinase 
inhibitors and possessed high antiproliferative activity on 
MCF-75. Another study by Huang has synthesized 
thioureas derivatives and then tested the cell growth 
inhibitory activity on NCl-H460, A549, HepG3, SKOV3 
cell lines. The results showed that the derivatives of 
these compounds have greater anticancer activity 
compared to 5-fluorouracil7. Kesuma has docked 
phenyltiourea derivatives with EGFR receptors, 
synthesized them and tested cytotoxic activity on MCF-7 
cells. The results showed that the phenyltiourea 
derivatives had better cytotoxic activities than 
hydroxyurea8. 
 
The benzoylurea derivative is also one of the promising 
anticancer agents for further development. Suhud has 
synthesized 1-benzyl-3-benzoylurea compound and 
tested its anticancer activity in MCF-7 cell culture. The 
results showed a better IC50 value obtained than 
hydroxyurea9. Diyah has docked benzoylurea derivatives 
with 3HNC receptors. Then the compounds were 
synthesized and tested for their cytotoxic activities using 
the Brine Shrimp Lethality Test (BST) method. All 
benzoylurea derivatives showed better LD50 values than 
hydroxyurea. Likewise, N, N'-dibenzoyl-N,N'-
diethylurea and N-N'-carbonylbis-(N-ethylbenzamide) 
compounds have been synthesized and tested its 
cytotoxic activities on MCF-7 cells. IC50 values obtained 
from the cytotoxic activity test showed that all 
benzoylurea derivatives had better cytotoxic activities 
than hydroxyurea10,11,12. 
 
The use of hydroxyurea is reported to cause many side 
effects, especially to thrombocythemia patients13. The 
hydrophilic groups in hydroxyurea cause lower 
penetration ability resulting in less optimal biological 
activity. Therefore, it is necessary to develop new 
anticancer drugs from urea derivatives that provide 
better membrane penetration capacity. 
 
In this study, two compounds were synthesized namely 
N-(4-bromo)-benzoyl-N'-phenylthiourea as a derivative 
of phenyltiourea and 4-(tert-butyl)-N-benzoylurea as a 
derivative of benzoylurea. This research began with the 
prediction of activity using in silico molecular modeling 
with the Molegro Virtual Docker 5.5 (MVD) program. In 
molecular modeling, docking is a method for predicting 
the affinity of a bond between a ligand and 
macromolecules such as proteins, lipids, carbohydrates, 
and nucleic acids that play an important role in signal 
transduction14. In silico technique is done by docking N-
(4-bromo)-benzoyl-N'-phenylthiourea and 4-(tert-butyl)-
N-benzoylurea compounds with HER-2 receptor (ID 
PDB: 3PP0)15. The N-(4-bromo)-benzoyl-N'-
phenylthiourea (4Br-BPTU) compound was synthesized 
from N-phenylthiourea and 4-bromobenzoyl chloride 
while 4-(tert-butyl)-N-benzoylurea (4TBBU) was 
synthesized from urea and 4-(tert-butyl)benzoyl chloride 
using acyl nucleophilic substitution16,17,18. The two 
synthesized compounds were further identified using an 
IR spectrometer, 1H-NMR, 13C-NMR, and a mass 
spectrometer18,19,20. 
 
In vitro cytotoxic activity of the two test compounds was 
carried out using the MTT (Microculture tetrazolium) 
assay21,22 in primary breast cancer cells. The MTT assay 
is based on metabolic reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) using the mitochondrial dehydrogenase enzyme 
into water-insoluble formazan crystals, which provides 
direct correlation of viable cells23. In this study, primary 
cells were obtained by isolating the biopsy tissue of 
HER2-positive breast cancer patients. The results of the 
cytotoxic assay were in the form of IC50 values which 
were then compared to hydroxyurea (HU) as a 
comparative compound. This research provides potential 
new anticancer candidates on primary cells of HER2-
positive breast cancer. 
 
MATERIAL AND METHODS: 
Chemicals and reagents: 
The materials needed for synthesis are N-phenylthiourea, 
4-bromobenzoyl chloride, urea, 4-(tert-butyl) benzoyl 
chloride (Sigma-Aldrich), tetrahydrofuran (THF), 
triethylamine (TEA), sodium bicarbonate, ethyl acetate, 
n-hexane, chloroform, methanol, and ethanol. The 
materials for primary breast cancer cell identification are 
CD133 biomarker, anti-HER2 monoclonal antibodies, 
PE and FITC anti-mouse IgG. Materials needed for in 
vitro cytotoxic activity test are Breast cancer cell 
cultures expressing HER2, culture media (Alpha MEM), 
Phosphate-buffered saline (PBS), trypsin, Penicillin-
Streptomycin, fungizone, fetal bovine serum (FBS), 
DMSO, 0.5 mg/mL 3-(4,5-Dimethylthiazol-2-yl)-2,5-




The instruments used were Fisher-John Electrothermal 
Mel-Temp, Bruker FT-IR spectrometer Alpha II, 1H-
NMR Spectroscopy and 13C-NMR Jeol ECS-400, and 
Waters Xevo Q-ToF mass spectrometer. The instruments 
used for cytotoxic testing are 5% CO2 incubator, LAF, 




blue and yellow micropipette, test tube, vortex, 96-well 
microplates, conical tube, inverted microscope, 
hemocytometer and ELISA reader. ChemBioDraw Ultra 
15.0 and Molegro Virtual Docker (MVD) ver. 5.5 was 




The synthesized compounds were predicted in advance 
for their cytotoxic activity using in silico molecular 
modeling. In silico technique was carried out through a 
simulation of drug-receptor interaction called docking 
using a computer. The two compounds were docked 
using the Molegro Virtual Docker (MVD) ver. 5.5 
program with HER2 receptor (ID PDB: 3PP0). 
Hydroxyurea (HU) is used as a comparative compound. 
 
4Br-BPTU and 4TBBU Synthesis: 
N-Phenylthiourea was mixed with THF and TEA in a 
round flask and added a drop-by-drop solution of 4-
bromo-benzoyl chloride to THF. Likewise, the same 
thing was done for mixing urea and 4-(tert-butyl)-
benzoyl chloride. It was carried out in an ice bath and 
stirred with a magnetic stirrer. Furthermore, the mixture 
is refluxed in a water bath. The reaction is complete if a 
stain is produced on a paper thin-layer chromatography 
(TLC) using the solvent system of hexane: chloroform 
(1:2) for 4Br-BPTU, ethyl acetate: hexane (1:2) for 
4TBBU and detected by UV chamber method18. Next, 
THF was evaporated in a rotary evaporator. After that 
add saturated sodium bicarbonate to the residue, filter 
the solid product on a Buchner funnel and wash it with a 
little cold water. Finally, recrystallize it with hot ethanol, 
filter off the crystals and dry them upon filter paper at 
temperature 50°C9,24. The structure of new compounds 
was identified using IR spectroscopy, 1H-NMR, 13C-
NMR, and HRMS18,19. 
 
Identification of Primary Breast Cancer Cells: 
Breast tissue obtained from the biopsy was isolated to 
obtain primary cells25,26. Then the isolated cells were 
identified using CD133 biomarkers by 
immunofluorescence to find out that the isolated cells 
were cancer cells. Furthermore, HER2 monoclonal 
antibodies are used to identify primary cells of breast 
cancer through immunofluorescence. 
 
Cytotoxicity Test: 
Primary breast cancer cell cultures were planted in 96 
wells plate and incubated for 24 hours in a CO2 
incubator. Then various concentrations of the two test 
compounds and HU were added. Each concentration was 
replicated three times. The controlled media used were 
those that do not contain cells but only culture media. It 
was incubated again for 24 hours and then each well was 
added 100µL of MTT reagent 0.5mg/mL followed by 
incubation for 4 hours27. After 4 hours of incubation, the 
MTT reaction was stopped by adding 100µL 10% SDS 
0.01N HCl into each well to solubilize the formazan 
crystals. The microplate was wrapped in paper and 
incubated at 37ºC for 24 hours, then its absorbance was 
read using ELISA reader at λ = 595nm and surviving cell 
fraction was calculated22,28,29. The IC50 values of both 
test compounds and HU as a comparison were obtained 
using probit analysis from SPSS version 25.021. 
 
RESULTS: 
The cytotoxic activity of 4Br-BPTU, 4TBBU and HU 
were predicted using in silico molecular modeling with a 
rerank score (RS) as the indicator. Compounds that have 
small RS values are predicted to have a large cytotoxic 
activity30,31. RS values of the test compounds and 
comparative compound can be seen in Figure 1. The 
interaction of the compounds with amino acids on the 




Fig. 1: Rerank Score (RS) of 4Br-BPTU, 4TBBU and HU 
 
Table 1: The Interactions of 4Br-BPTU, 4TBBU, and HU with Amino Acids on the HER2 Receptor (3PP0) 





























4Br-BPTU 2S 3S 7S 5S 1S 1S 1S 1S 4S 1S - - - - 
4TBBU 1S  1S  1S 1S 1S  5S  1S 1H 
1S 
- - 
HU - - - - - - - - - - - - 1H 1S 
H: hydrogen bond; S: Steric Interactions (Van der Waals and Hydrophobic Bonds) 








Fig. 2: Hydrogen bonding (blue dashed line) and steric interactions (red dashed line) between the compounds and amino acids on active 
site HER2 receptor: 4Br-BPTU (a), 4TBBU (b) and HU (c) 
 
After predicting cytotoxic activity through in silico, 4Br-
BPTU and 4TBBU compounds were synthesized. The 
4Br-BPTU compound was synthesized from 4-bromo-
benzoyl chloride with N-phenylthiourea and the 4TBBU 
compound was synthesized from 4-(tert-butyl)-benzoyl 
chloride with urea. The structure of the synthesis 
compounds is shown in Figure 3. 
 
 
Fig. 3: The structure of 4Br-BPTU (a) and 4TBBU (b) 
 
The structure of the synthesized compound identified 
using the IR, 1H-NMR, 13C-NMR and HRMS 
spectrometers is as follows: 
 
N-(4-bromo)-benzoyl-N’-phenylthiourea: 
The compound was in the form of yellowish white 
crystal with a yield of 56 %, m.p 180-182°C. 1H-NMR 
(DMSO-d6, 400MHz) δ: 7.28 (t, J 7.2 Hz, 1H, Ar-H), 
7.43 (t, J 7.2 Hz, 2H, Ar-H), 7.69 (d, J 8.0 Hz, 2H, Ar-
H), 7.76 (d, J 9.2 Hz, 2H, Ar-H), 7.92 (d, J 9.2 Hz, 2H, 
Ar-H), 11.67 (s, 1H, O=C-NH-C=S), 12.50 (s, 1H, S=C-
NH-Ar). 13C-NMR (DMSO-d6, 100 MHz) δ: 124.30 (1C, 
Ar), 126.33 (2C, Ar), 127.05 (1C, Ar), 128.66 (2C, Ar), 
130.75 (2C, Ar), 131.37 (2C, Ar), 131.43 (1C, Ar), 
137.94 (1C, Ar), 167.37 (1C, C=O), 179.95 (1C, C=S). 
IR, υmax (cm-1): 1660 (C=O amide), 1067 and 837 (C=S), 
1588 and 1469 (C=C aromatic), 3309 and 1588 (NH 
strecth secondary amide). HRMS (m/z): C14H10N2OSBr 
(M-H)- = 334.9842 and Calc. Mass = 334.9809. 
 
4-(tert-butyl)-N-benzoylurea: 
This yellowish white crystal compounds has a yield of 
29 %, m.p. 168 - 170°C. 1H-NMR (DMSO-d6, 400MHz) 
δ: 7.40 (s, 1H, O=C-NH2(1)), 8.09 (s, 1H, O=C-NH2(2)), 
7.52 ( App.d, J 8.4 Hz, 2H, Ar-H), 7.92 ( App.d, J 8.4 
Hz, 2H, Ar-H), 10.48 (s, 1H, O=C-NH-C=O), 1.30 (s, 
9H, -C-(CH3)3). 13C-NMR (DMSO-d6, 100 MHz) δ: 
30.84 (3C, C-(CH3)3), 34.79 (1C, -C-(CH3)3), 155.74 
(1C, Ar), 125.32 (2C, Ar), 128.08 (2C, Ar), 129.88 (1C, 
Ar), 167.88 (1C, O=C-NH), 154.30 (1C, HN-C=O-NH2). 
IR, υmax (cm-1): 1692 and 1655 (pair C=O amide), 1605 
and 1468 (C=C aromatic), 3321 (NH strecth secondary 
amide), 3214 and 3148 (NH2 stretch primary amide). 
HRMS (m/z): C12H17N2O2 (M+H)+ = 221.1255 and Calc. 
Mass = 221.1245. 
 
In vitro cytotoxic activity of the test compounds and 
comparative compound were carried out on primary 
breast cancer cells. Primary breast cancer cells were 
identified using CD133 biomarker (Figure 4a) and anti-
HER2 monoclonal antibodies using immunofluorescence 
technique (Figure 4b). 






Fig. 4: The identification of CD133 and HER2 in Breast Cancer 
Cells through the Immunofluorescence Technique. Cells that 
Express CD133 is Red Fluorescent and cells that express HER2 is 
green fluorescent: CD133 in breast cancer cells (a), HER2 in breast 
cancer cells (b) 
 
Figure 5 displays the results of a cytotoxic test in the 




Fig. 5: IC50 Values of 4Br-BPTU, 4TBBU, and HU Compounds 
 
DISCUSSION: 
Based on Figure 1, the RS values of 4Br-BPTU and 
4TBBU were smaller than those of HU. Thus, they were 
predicted to have better cytotoxic activities than HU as a 
comparison compound. Meanwhile, the RS value of 4Br-
BPTU was smaller than 4TBBU, it means that the 
cytotoxic activity of 4Br-BPTU was better than 4TBBU. 
The number of hydrogen bonds and steric interactions 
illustrates the strength of ligand-receptor bonds. The 
more number of chemical bonds causes the ligand-
receptor bond to be more strength and then affects the 
biological activity of the compound18. Table 1 and 
Figure 2 depict that 4Br-BPTU had more steric 
interactions than 4TBBU even without hydrogen bonds. 
4TBBU compounds have one hydrogen bond and fewer 
steric interactions with amino acids at HER2 receptors. 
Therefore, the RS value of 4Br-BPTU to be smaller than 
the 4TBBU compound. HU compound had one hydrogen 
bond and one steric bond so the RS value of hydroxyurea 
was much higher. 
 
The synthesized compound is purely based on IR 
spectroscopy,1 H-NMR,13 C-NMR and mass spectrum as 
stated in the results section of this study. Then the 
synthesis compound was tested in vitro cytotoxic activity 
on primary breast cancer cells. The primary breast 
cancer cells were isolated from breast tissue of breast 
cancer patients. Isolated breast cancer cells were 
identified using CD133 biomarkers. CD133 or called 
prominin-1 is a single-chain transmembrane 
glycoprotein, mainly placed protruding inward from the 
plasma membrane cell and associated with cholesterol. 
Cells that express high CD133 show high proliferation 
ability and differentiation and increase the expression of 
proteins involved in metastasis and resistance to 
anticancer drugs. CD133 is expressed in solid tumors so 
that it is known as an important biomarker to identify 
and isolate specific cellular subpopulations, which are 
cancer stem cells (CSC) from several types of cancer 
including breast cancer32,33. Based on Figure 4a can be 
seen that positive cells express CD133 (red fluorescent) 
showing that the isolated cells are cancer cells. Thus, this 
study is focused on breast cancer cells that express 
HER2. The cells that have been identified as positive 
with CD133 biomarkers must be tested positive for 
expressing HER2 by immunofluorescence using HER2 
monoclonal antibodies. The human epidermal growth 
factor receptor (HER) family of receptors plays a central 
role in the pathogenesis of several human cancers. They 
regulate cell growth, survival, and differentiation via 
multiple signal transduction pathways and participate in 
cellular proliferation and differentiation. Breast cancers 
can have up to 25 – 50 copies of the HER2 gene, and up 
to a 40-100-fold increase in HER2 protein resulting in 2 
million receptors expressed at the tumor cell surface34. 
Figure 4b shows that cells with green fluorescence are 
cells that express HER2. 
 
Based on Figure 5, the 4Br-BPTU compound had the 
smallest IC50 value among the three compounds tested. 
Therefore 4Br-BPTU had the best cytotoxic activity. 
This is consistent with the RS value and the number of 
chemical bonds with amino acids on the HER2 receptor. 
The RS value of 4Br-BPTU was smallest and its number 




and 4-(tert-butyl)-N-benzoylurea (4TBBU) which have 
been synthesized had higher cytotoxic activity against 
primary breast cancer cells than hydroxyurea. N-(4-
bromo)-benzoyl-N’-phenylthiourea was more potent than 
4-(tert-butyl)-N-benzoylurea. It is highly recommended 
that N-(4-bromo)-benzoyl-N’-phenylthiourea be 
developed further as an anticancer candidate for HER2-
positive breast cancer. 
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